TJC0265 series compounds are autotaxin inhibitors, the therapeutic mechanism of anti-fibrotic effect on which target has been reported by the literature. Comparing with the lead compounds by other international pharmas, TJC0265 series compounds have shown equal or better efficacy in various NASH and anti-fibrotic animal models. Lead optimizations of back-up series are under process. Evaluation of toxicology and safety pharmacology are also under preparation.